ClinicalTrials.gg
CompletedNCT02374437Updated Feb 27, 2015

Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol and Food Effect in Healthy Volunteers

A Phase 1 interventional study of Aramchol and Placebo in Healthy Volunteers, sponsored by Galmed Pharmaceuticals Ltd. Completed. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-27.

Sponsored by Galmed Pharmaceuticals Ltd · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

This is a single-site, randomized, partly double-blind, placebo-controlled study of Aramchol in sixty six (66) healthy male volunteers.

In each part of the study subjects will be enrolled in the study within 28 days before drug administration(s).

The study will consist of three parts and the subjects will be assigned to three Parts.

Read the detailed description

This is a single-site, randomized, partly double-blind, placebo-controlled study of Aramchol in sixty six (66) healthy male volunteers.

In each part of the study subjects will be enrolled in the study within 28 days before drug administration(s).

The study will consist of three parts and the subjects will be assigned to three Parts as follows:

Part A - single escalating doses:

The purpose of this part is to evaluate the pharmacokinetics, safety and tolerability of Aramchol tablets at single doses of either 200 mg or 400 mg.

Twelve (12) subjects will be randomized to receive , following an overnight 10 hours fast, a single dose of either:

  • Administration A: 1×200 mg Aramchol tablet (6 subjects)
  • Administration B: 1×400 mg Aramchol tablet (6 subjects) Subjects will be admitted to the Clinical Research Center (CRC) in the evening before study drug administration (Day 0) and will remain in-house for 36 hours after dosing. Blood samples for Aramchol concentrations will be drawn for 36 hours at designated time points as described below. Additional ambulatory samples will be collected at 48, 72, 96 and 144 hours post-dose. Subjects will be continuously monitored for safety.

An End-of Study/Safety Follow-up visit will take place on the last PK sampling day, i.e. 144 hours post-dose.

Part B - food effect:

The purpose of this part is to evaluate the effect of high fat high calorie meal on the pharmacokinetics of a single dose of Aramchol and to assess the safety and tolerability of a single 600 mg dose.

This part is designed as a randomized, two period crossover food-effect study.

Eighteen (18) subjects will be randomized to receive one of two administration sequences (C-D or D-C) as follows:

  • Administration C: 1×200 mg +1×400 mg Aramchol tablets under fasting conditions (fasting for at least 10 hours before and 4 hours after dosing)
  • Administration D: 1×200 mg +1×400 mg Aramchol tablets under fed conditions (fasting for at least 10 hours before dosing, consumption of a high calorie high fat meal within 30 minutes prior to drug administration and no food for additional 4 hours after dosing) In each period of this part, subjects will be admitted to the Clinical Research Center (CRC) in the evening before study drug administration (Day 0) and will remain in-house for 36 hours after dosing. Blood for Aramchol concentrations will be drawn for 36 hours at designated time points as described below. Additional ambulatory samples will be collected at 48, 72, 96 and 144 hours post-dose. Subjects will be continuously monitored for safety.

There will be a wash-out period of at least 14 days between each dosing session.

An End-of Study/Safety Follow-up visit will take place on the last PK sampling day of the second dosing period, i.e. 144 hours after second dose.

The PK profile of subjects who received administration C (i.e. 600 mg Aramchol tablet under fasting conditions) will be compared with that of subjects who received 200 and 400 mg Aramchol tablet under fasting conditions in Part A.

Part C - multiple doses:

The purpose of this part is to evaluate the pharmacokinetics, safety and tolerability of Aramchol tablets at multiple administrations of 3 different doses.

This part is designed as a randomized, double blind, double-dummy, placebo-controlled multiple-dose study.

Thirty six (36) subjects will participate in this part and will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days. Drug administration will be preceded by a light breakfast consumed within 1 hour prior to dosing (the composition of which is described in Appendix III). All drugs will be administered by the study staff except Dose No. 6 which the subjects will take at home.

In order to maintain blinding, all subjects will receive two tablets on each dosing, according to the following administrations:

  • Administration E: 1×200 mg Aramchol tablet + 1×400 mg Placebo tablet
  • Administration F: 1×200 mg Placebo tablet + 1×400 mg Aramchol tablet
  • Administration G : 1×200 mg Aramchol tablet + 1×400 mg Aramchol tablet
  • Administration H: 1×200 mg Placebo tablet + 1×400 mg Placebo tablet

Treatment assignment will be as follows:

Subjects will be admitted to the Clinical Research Center (CRC) in the evening before the first study drug administration (Day 0) and will remain in-house for 24 and 36 hours after first (Day 1) and last (Day 10) doses, respectively. PK blood samples will be drawn on Day 1 for 24 hours at designated time points as described below. Additionally, ambulatory pre-dose (trough) samples will be drawn before dosing on Days 2, 3, 4, 5, 7, 8, and 9. On Day 10 blood samples will be collected for 36 hours at designated time points as described below and during additional ambulatory visits at 48, 96, 120, 144, 168 and 192 hours post-dose.

Subjects will be continuously monitored for safety. An End-of Study/Safety Follow-up visit will take place on the last PK sampling day of the study, i.e. 144 hours (for Parts A and B) and 192 hours (for Part C) after the last dose administration.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Galmed Pharmaceuticals Ltd is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, males subjects between 18-50 years (inclusive)
  2. 21.0\<\< 29.9kg/m2
  3. Non-smoking (by declaration) for a period of at least 3 months before screening visit.
  4. Subjects in general good health in the opinion of the investigator as determined by medical history, vital signs and a physical examination.
  5. No significant abnormalities in (e.g. prolonged QTC, prolonged PR interval) done at screening and on Days (0) before dosing session.
  6. No abnormalities in hematology, blood chemistry, or urinalysis lab tests at screening.
  7. No known history of alcohol or drug abuse. Subjects with negative urinary drugs of abuse screen determined on Day (0) before dosing session(s)
  8. Negative , or serology tests as evaluated at screening.
  9. Subjects must be able to adhere to the visit schedule and protocol requirements and be available to complete the study.
  10. Subjects must agree to use adequate measures (condom in combination with a spermicidal gel or foam) during the study and up to 15 days after the last study drug administration.
  11. Subjects must satisfy a medical examiner about their fitness to participate in the study.
  12. Subjects must provide written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Documented history or on-going symptoms of any gastrointestinal disorder involving motility, gastric acid or gastric emptying or malabsorption, including but not limited to, peptic ulcer disease, gastroesophageal reflux, dyspepsia, gastroparesis, chronic diarrhea, chronic constipation, gall bladder disease, pancreatitis, lactose intolerance and celiac disease.
  2. History of esophageal, gastric, biliary, or intestinal surgery (excluding herniotomy and appendectomy which are not related to gastrointestinal disorders).
  3. Known history of significant medical disorder, which in the investigator's judgment contraindicates administration of the study medications.
  4. Any abnormality upon physical examination or in the clinical laboratory tests at screening visit.
  5. Use of any prescription or over-the-counter (OTC) medications, vitamins and herbal or dietary supplements within 14 days prior to dosing. Paracetamol or ibuprofen for symptomatic relief of pain is allowed until 24 hours prior to the study drug administration.
  6. Subjects who have taken anticholinergic or other drugs known to affect gastrointestinal motility within 7 days prior to the first dosing
  7. Treatment with any drugs with known hepatic enzyme-inducing or inhibiting agents (such as barbiturates, phenothiazines, cimetidine, carbamazepine, etc.) within 30 days prior to dosing.
  8. Known and/or allergy to any drugs.
  9. Adherence (for whatever reason) to an abnormal diet during the 4 weeks prior to the study, or subjects with recent significant change in body weight
  10. Any acute illness (e.g. acute infection) within 48 hours prior to the first study drug administration, which is considered of significance by the Principal Investigator.
  11. Participation in another clinical trial with drugs, received within 3 months prior to dosing (calculated from the previous study's last dosing date).
  12. Subjects who donated blood in the three months or received blood or plasma derivatives in the six months preceding study drug administration.
  13. Subjects with inability to communicate well with the investigators and CRC staff (i.e., language problem, poor mental development or impaired cerebral function).
  14. Inability to fast or consume the food provided in the study (including any known food allergies or food restrictions).
  15. Subjects who are non-cooperative or unwilling to sign consent form.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Active comparator
    PART A (single dose)-200 mg

    200 mg ARAMCHOL

    Drug: Aramchol

  • Active comparator
    PART A (single dose)-400 mg

    400 mg ARAMCHOL

    Drug: Aramchol

  • Active comparator
    Part B ( food effect)- -Fasting

    600 mg Aramchol tablets under fasting conditions (fasting for at least 10 hours before and 4 hours after dosing)

    Drug: Aramchol

  • Active comparator
    Part B ( food effect)- -Fed

    600 mg Aramchol tablets under fed conditions (fasting for at least 10 hours before dosing, consumption of a high calorie high fat meal within 30 minutes prior to drug administration and no food for additional 4 hours after dosing)

    Drug: Aramchol

  • Active comparator
    Part C ( multiple doses)- 200 mg

    200 mg Aramchol tablets for ten consecutive days.

    Drug: Aramchol

  • Active comparator
    Part C ( multiple doses)- 400 mg

    400 mg Aramchol tablets for ten consecutive days.

    Drug: Aramchol

  • Active comparator
    Part C ( multiple doses)- 600 mg

    600 mg Aramchol tablets for ten consecutive days.

    Drug: Aramchol

  • Placebo comparator
    Part C ( multiple doses)- Placebo

    Placebo tablets for ten consecutive days.

    Drug: Placebo

Interventions

  • PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.

  • DrugPlacebo

    PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: Part A:Pre-dose (within 60 min before dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 30, 36, 48(±60 min), 72 (±60 min), 96 (±60 min), 144 (±60 min) hours post-dose. Part C:Dosing days 1-10

  2. Area under the plasma concentration time curve (AUC)

    Time frame: Part A:Pre-dose (within 60 min before dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 30, 36, 48(±60 min), 72 (±60 min), 96 (±60 min), 144 (±60 min) hours post-dose. Part C:Dosing days 1-10

  3. Maximum plasma concentration (Cmax)

    Time frame: Part B: For each treatment period: Pre-dose (within 60 min before dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 30, 36, 48(±60 min), 72(±60 min), 96(±60 min), 144 (±60 min) hours post dose.

  4. Area under the plasma concentration time curve (AUC)

    Time frame: Part B: For each treatment period: Pre-dose (within 60 min before dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 30, 36, 48(±60 min), 72(±60 min), 96(±60 min), 144 (±60 min) hours post dose.

  5. Maximum plasma concentration (Cmax)

    Time frame: Part C: day 1 and day 10

  6. Area under the plasma concentration time curve (AUC)

    Time frame: Part C: day 1 and day 10

Secondary outcomes

  1. Adverse event (AE) profile

    Adverse event records in patients file

    Time frame: Part A:Pre-dose (within 60 min before dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 30, 36, 48(±60 min), 72 (±60 min), 96 (±60 min), 144 (±60 min) hours post-dose. Part C:Dosing days 1-10

  2. Adverse event (AE) profile

    Adverse event records in patients file

    Time frame: Part B: For each treatment period: Pre-dose (within 60 min before dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 30, 36, 48(±60 min), 72(±60 min), 96(±60 min), 144 (±60 min) hours post dose.

  3. Adverse event (AE) profile

    Adverse event records in patients file

    Time frame: Part C:Dosing days 1 and 2: pre-dose (within 60 min before first dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18 and 24 (before second dosing) hours after drug administration+ day 3-10

  4. Clinical laboratory safety tests

    blood test

    Time frame: Part A:Pre-dose (within 60 min before dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 30, 36, 48(±60 min), 72 (±60 min), 96 (±60 min), 144 (±60 min) hours post-dose. Part C:Dosing days 1-10

  5. Clinical laboratory safety tests

    blood test

    Time frame: Part B: For each treatment period: Pre-dose (within 60 min before dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 30, 36, 48(±60 min), 72(±60 min), 96(±60 min), 144 (±60 min) hours post dose.

  6. Clinical laboratory safety tests

    blood test

    Time frame: Part C:Dosing days 1 and 2: pre-dose (within 60 min before first dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18 and 24 (before second dosing) hours after drug administration+ day 3-10

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2015
First posted
Feb 27, 2015
Start
Apr 2014
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Last update
Feb 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02374437
Lead sponsor
Galmed Pharmaceuticals Ltd
Responsible party
Sponsor
First posted
Feb 27, 2015
Start date
Apr 2014
Primary completion
Dec 2014
Completion
Dec 2014
Last update
Feb 27, 2015

Study contacts

Maya Halpern, MD
study director · GALMED PHARMCEUTICALS
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aramchol

Start the discussion